« Return to News | Awards & Advancement

Trovagene appoints Erlander chief scientific officer

Monday, March 4, 2013 02:15 PM

San Diego-based Trovagene, a developer of transrenal molecular diagnostics, has named Mark Erlander, Ph.D., chief scientific officer.  Erlander has more than 18 years of experience directing research teams with a strong focus in oncology-based molecular diagnostics. 

Erlander will direct the clinical development program for the company's portfolio of transrenal and urine-based molecular diagnostic assays. Clinical studies will initially focus on Trovagene's oncogene mutation tests currently in development. Erlander will also oversee the ongoing clinical program for Trovagene's human papilloma virus (HPV) carrier screening assay.

Previously he was chief scientific officer of bioTheranostics, a molecular oncology diagnostics laboratory based in San Diego, and a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson).  He holds 38 issued U.S. patents in diagnostics, therapeutics and genomic technologies, and is author of 73 scientific publications with 56 peer-reviewed original articles and 17 review/chapter publications.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.